Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shionogi Renews 10-Year Goal After Infectious Disease Success

Push For Faster Xocova Growth

Executive Summary

Shionogi renews its 10-year strategic plan originally announced in 2020 following the successful debut of COVID-19 therapeutic Xocova. Fulfilling its 2025 goals ahead of schedule, its new strategy focuses on HIV and COVID-19 and new product launches.

You may also be interested in...

Japan Q1 Roundup: High Hopes For Leqembi And Veozah, Forex Give And Take

Daiichi Sankyo, Chugai and Shionogi all marked double-digit revenue growth in the fiscal first quarter, while Astellas and Takeda saw some slow down. New products including Veozah and Leqembi buoyed performances, while the the expected upcoming US approval of a subcutaneous formulation may help restore Entyvio’s growth trajectory.

Japan Widens Flu Stockpiles With Shionogi's Xofluza

New supplies of Shionogi's antiviral Xofluza will be used to boost Japan's national stocks of flu therapeutics, along with others including Tamiflu and Relenza, to increase preparedness for new viral strains. While resistance concerns for Xofluza appear to be reducing, local experts supported the decision on condition use is limited to those under 12 years of age.

Shionogi's Xocova Extends Global Reach Through First MPP Sublicenses

The first sublicensing deals through MPP for Shionogi's oral COVID antiviral Xocova with seven firms in China, India, Ukraine and Vietnam suggest the global debut of generic versions will come earlier than usual after the original, which continues in multiple global Phase III programs in various settings. While sales hopes are high, the drug may also be hit by a price cut in its first and biggest market so far – Japan.


Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts